Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: GlobeNewswire
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacksStrengthened executive committee with hiring of David Nassif, J.D., Chief Financial Officer, and Stefan Abele, Ph.D., as Chief Technical Operations OfficerUK Innovation Passport awarded to deucrictibant for both the on-demand and prophylactic treatment of HAE attacksEnded 2023 with cash and cash equivalents of approximately €391 million ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. “2024 is off to a strong start, supported by the incredible momen
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Pharvaris (NASDAQ: PHVS) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.MarketBeat
- Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Morgan Stanley from $35.00 to $34.00. They now have an "overweight" rating on the stock.MarketBeat
- Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Pharvaris (NASDAQ: PHVS) had its price target raised by analysts at JMP Securities from $49.00 to $50.00. They now have a "market outperform" rating on the stock.MarketBeat
- Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.MarketBeat
PHVS
Earnings
- 5/8/23 - Beat
PHVS
Sec Filings
- 4/23/24 - Form 144
- 4/15/24 - Form 144
- 4/12/24 - Form F-3ASR
- PHVS's page on the SEC website